Evaluating the pharmacological activities of Aloe perryi–Silver nanoparticles induced apoptosis against colon cancer cells (HCT‐116)

Aloe perryi has been studied and possesses several activities, including antibacterial, antiparasitic, and anticancer properties. In this study, A. perryi was used as a reducing agent of silver ions into silver nanoparticles. Aloe perryi–silver nanoparticles (APS‐NPs) were characterized and evaluated using characterization techniques. However, the antioxidative, antibacterial, and anticancer assays were studied to evaluate the pharmacological activities of APS‐NPs. APS‐NPs were developed and changed to dark brown and the maximum absorption was 442 nm. SEM (5–583 nm), TEM (4–110 nm), XRD (21.84 nm), and zeta potential analysis (63.39 nm) revealed that the APS‐NPs were nano‐sized, and the APS‐NPs had a cubic crystalline structure, according to the XRD results. FTIR analysis suggested that functional groups of A. perryi metabolites were involved in forming APS‐NPs. The zeta potential indicated that the APS‐NPs were negatively charged (−32 mV), suggesting good stability. APS‐NPs showed significant antioxidative stress activity by reducing DPPH‐free radicles in a dose‐dependent manner. APS‐NPs‐induced antibacterial effect against Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), and Acinetobacter baumannii (A. baumannii). APS‐NPs reduced the cell viability and cell migration of the human colon tumor cell line (HCT 116) compared with controls, indicating that APS‐NPs could play a role in reducing metastasis and inducing cell apoptosis against colon cancer. In conclusion, the nanoparticle synthesis from A. perryi extract demonstrated excellent antioxidant, antibacterial, and anticancer activities, thus suggesting that our APS‐NPs have the potential to be used as antioxidative and antibacterial in food and pharmaceutical industries. Synthesis of silver nanoparticles via using Aloe perryi as a reducing agent, and illustrating the characterization studies of Aloe perryi–silver nanoparticles and their pharmacological activity against HCT‐116 colon cancer cells.